Sanofi SA (SNY)
47.97
+0.15
(+0.31%)
USD |
NASDAQ |
Nov 15, 16:00
47.98
+0.01
(+0.02%)
After-Hours: 20:00
Sanofi Research and Development Expense (TTM): 7.755B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 7.755B |
| June 30, 2024 | 7.529B |
| March 31, 2024 | 7.471B |
| December 31, 2023 | 7.283B |
| September 30, 2023 | 7.131B |
| June 30, 2023 | 7.069B |
| March 31, 2023 | 7.058B |
| December 31, 2022 | 7.050B |
| September 30, 2022 | 6.998B |
| June 30, 2022 | 6.952B |
| March 31, 2022 | 6.870B |
| December 31, 2021 | 6.725B |
| September 30, 2021 | 6.401B |
| June 30, 2021 | 6.177B |
| March 31, 2021 | 6.362B |
| June 30, 2020 | 6.349B |
| March 31, 2020 | 6.643B |
| December 31, 2019 | 6.737B |
| September 30, 2019 | 6.783B |
| June 30, 2019 | 6.969B |
| March 31, 2019 | 6.948B |
| December 31, 2018 | 6.947B |
| September 30, 2018 | 6.756B |
| June 30, 2018 | 6.634B |
| March 31, 2018 | 6.367B |
| Date | Value |
|---|---|
| December 31, 2017 | 6.189B |
| September 30, 2017 | 6.015B |
| June 30, 2017 | 5.802B |
| March 31, 2017 | 5.752B |
| December 31, 2016 | 5.720B |
| September 30, 2016 | 5.525B |
| June 30, 2016 | 5.668B |
| March 31, 2016 | 5.600B |
| December 31, 2015 | 5.545B |
| September 30, 2015 | 5.682B |
| June 30, 2015 | 5.695B |
| March 31, 2015 | 5.947B |
| December 31, 2014 | 6.200B |
| September 30, 2014 | 6.180B |
| June 30, 2014 | 6.228B |
| March 31, 2014 | 6.147B |
| December 31, 2013 | 6.114B |
| September 30, 2013 | 6.398B |
| June 30, 2013 | 6.262B |
| March 31, 2013 | 6.300B |
| December 31, 2012 | 6.309B |
| September 30, 2012 | 6.264B |
| June 30, 2012 | 6.559B |
| March 31, 2012 | 6.698B |
| December 31, 2011 | 6.666B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
6.177B
Minimum
Jun 2021
7.755B
Maximum
Sep 2024
6.920B
Average
6.975B
Median
Research and Development Expense (TTM) Benchmarks
| AstraZeneca PLC | 11.98B |
| GSK PLC | 8.123B |
| Eli Lilly and Co | 10.53B |
| Novavax Inc | 451.49M |
| Regeneron Pharmaceuticals Inc | 4.897B |